Cargando…
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associat...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110597/ https://www.ncbi.nlm.nih.gov/pubmed/37069173 http://dx.doi.org/10.1038/s41523-023-00534-1 |
| _version_ | 1785027293690724352 |
|---|---|
| author | Zattarin, Emma Presti, Daniele Mariani, Luigi Sposetti, Caterina Leporati, Rita Menichetti, Alice Corti, Chiara Benvenuti, Chiara Fucà, Giovanni Lobefaro, Riccardo Ligorio, Francesca Provenzano, Leonardo Vingiani, Andrea Del Vecchio, Marta Griguolo, Gaia Sirico, Marianna Bernocchi, Ottavia Marra, Antonio Zagami, Paola Agostinetto, Elisa Jacobs, Flavia Di Mauro, Pierluigi Esposito, Andrea Giorgi, Carlo Alberto Lalli, Luca Boldrini, Laura Giacchetti, Pier Paolo Berton Schianca, Ambra Carnevale Guarneri, Valentina Pedersini, Rebecca Losurdo, Agnese Zambelli, Alberto Generali, Daniele Criscitiello, Carmen Curigliano, Giuseppe Pruneri, Giancarlo de Braud, Filippo Dieci, Maria Vittoria Vernieri, Claudio |
| author_facet | Zattarin, Emma Presti, Daniele Mariani, Luigi Sposetti, Caterina Leporati, Rita Menichetti, Alice Corti, Chiara Benvenuti, Chiara Fucà, Giovanni Lobefaro, Riccardo Ligorio, Francesca Provenzano, Leonardo Vingiani, Andrea Del Vecchio, Marta Griguolo, Gaia Sirico, Marianna Bernocchi, Ottavia Marra, Antonio Zagami, Paola Agostinetto, Elisa Jacobs, Flavia Di Mauro, Pierluigi Esposito, Andrea Giorgi, Carlo Alberto Lalli, Luca Boldrini, Laura Giacchetti, Pier Paolo Berton Schianca, Ambra Carnevale Guarneri, Valentina Pedersini, Rebecca Losurdo, Agnese Zambelli, Alberto Generali, Daniele Criscitiello, Carmen Curigliano, Giuseppe Pruneri, Giancarlo de Braud, Filippo Dieci, Maria Vittoria Vernieri, Claudio |
| author_sort | Zattarin, Emma |
| collection | PubMed |
| description | Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting. |
| format | Online Article Text |
| id | pubmed-10110597 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101105972023-04-19 Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors Zattarin, Emma Presti, Daniele Mariani, Luigi Sposetti, Caterina Leporati, Rita Menichetti, Alice Corti, Chiara Benvenuti, Chiara Fucà, Giovanni Lobefaro, Riccardo Ligorio, Francesca Provenzano, Leonardo Vingiani, Andrea Del Vecchio, Marta Griguolo, Gaia Sirico, Marianna Bernocchi, Ottavia Marra, Antonio Zagami, Paola Agostinetto, Elisa Jacobs, Flavia Di Mauro, Pierluigi Esposito, Andrea Giorgi, Carlo Alberto Lalli, Luca Boldrini, Laura Giacchetti, Pier Paolo Berton Schianca, Ambra Carnevale Guarneri, Valentina Pedersini, Rebecca Losurdo, Agnese Zambelli, Alberto Generali, Daniele Criscitiello, Carmen Curigliano, Giuseppe Pruneri, Giancarlo de Braud, Filippo Dieci, Maria Vittoria Vernieri, Claudio NPJ Breast Cancer Brief Communication Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting. Nature Publishing Group UK 2023-04-17 /pmc/articles/PMC10110597/ /pubmed/37069173 http://dx.doi.org/10.1038/s41523-023-00534-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Brief Communication Zattarin, Emma Presti, Daniele Mariani, Luigi Sposetti, Caterina Leporati, Rita Menichetti, Alice Corti, Chiara Benvenuti, Chiara Fucà, Giovanni Lobefaro, Riccardo Ligorio, Francesca Provenzano, Leonardo Vingiani, Andrea Del Vecchio, Marta Griguolo, Gaia Sirico, Marianna Bernocchi, Ottavia Marra, Antonio Zagami, Paola Agostinetto, Elisa Jacobs, Flavia Di Mauro, Pierluigi Esposito, Andrea Giorgi, Carlo Alberto Lalli, Luca Boldrini, Laura Giacchetti, Pier Paolo Berton Schianca, Ambra Carnevale Guarneri, Valentina Pedersini, Rebecca Losurdo, Agnese Zambelli, Alberto Generali, Daniele Criscitiello, Carmen Curigliano, Giuseppe Pruneri, Giancarlo de Braud, Filippo Dieci, Maria Vittoria Vernieri, Claudio Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title_full | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title_fullStr | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title_full_unstemmed | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title_short | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
| title_sort | prognostic significance of her2-low status in hr-positive/her2-negative advanced breast cancer treated with cdk4/6 inhibitors |
| topic | Brief Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110597/ https://www.ncbi.nlm.nih.gov/pubmed/37069173 http://dx.doi.org/10.1038/s41523-023-00534-1 |
| work_keys_str_mv | AT zattarinemma prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT prestidaniele prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT marianiluigi prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT sposetticaterina prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT leporatirita prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT menichettialice prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT cortichiara prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT benvenutichiara prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT fucagiovanni prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT lobefaroriccardo prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT ligoriofrancesca prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT provenzanoleonardo prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT vingianiandrea prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT delvecchiomarta prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT griguologaia prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT siricomarianna prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT bernocchiottavia prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT marraantonio prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT zagamipaola prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT agostinettoelisa prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT jacobsflavia prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT dimauropierluigi prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT espositoandrea prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT giorgicarloalberto prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT lalliluca prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT boldrinilaura prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT giacchettipierpaoloberton prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT schiancaambracarnevale prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT guarnerivalentina prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT pedersinirebecca prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT losurdoagnese prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT zambellialberto prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT generalidaniele prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT criscitiellocarmen prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT curiglianogiuseppe prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT prunerigiancarlo prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT debraudfilippo prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT diecimariavittoria prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors AT verniericlaudio prognosticsignificanceofher2lowstatusinhrpositiveher2negativeadvancedbreastcancertreatedwithcdk46inhibitors |